Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine.
about
Getting the balance right: Established and emerging therapies for major depressive disordersTolerability and safety of fluvoxamine and other antidepressants.Accelerated hypertension after venlafaxine usageThe influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.Mother-infant antidepressant concentrations, maternal depression, and perinatal eventsReduction of Methylphenidate Induced Anxiety, Depression and Cognition Impairment by Various doses of Venlafaxine in Rat.Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity.Treatment of anxiety disorders with venlafaxine XR.The impact of CYP allelic variation on antidepressant metabolism: a review.A novel prodrug strategy to improve the oral absorption of O-desmethylvenlafaxine.Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram.Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.Venlafaxine versus applied relaxation for generalized anxiety disorder: a randomized controlled study on clinical and electrophysiological outcomes.Phenolic esters of O-desmethylvenlafaxine with improved oral bioavailability and brain uptake.Chirality of Modern Antidepressants: An Overview.
P2860
Q24610225-A3765788-167C-468A-8345-46456211DFD3Q33995120-0F13E5FD-BF31-41FF-A99A-BB034064AE28Q34311469-A7CC610A-02B3-455B-9438-1200B9517567Q34453981-D1DDA4FA-B95B-497D-90F2-9838A6BE3F47Q35172179-B8C5F4FD-3B1A-494A-95DD-581F88447F89Q35716678-CA027188-99FE-4B5D-A927-9566DB860E8DQ35825751-9D5A139D-3DE4-4DDF-8C89-4E6604CD21C7Q36419538-1931E48D-CE92-496B-AA84-B7112A091AC8Q36725210-0A0F15FE-9CA3-45E2-B67E-A445BA700DD6Q37204088-6E6AD496-2C47-4F08-B22C-65DACF2A0F70Q45139118-FE4331A8-EAF6-4958-98C0-95FCDA750D42Q47267937-4EC99AE9-249A-40A7-907C-4F0FD88BFC4BQ48160427-9D4BDDE7-E51C-44A4-91BC-62791A8C9944Q48826911-EC70977A-83C0-4203-9F3E-F78311912B6CQ49299197-048F88E0-2471-46AE-ADB9-99818A2B3F80
P2860
Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Review of the pharmacokinetics ...... essants: focus on venlafaxine.
@ast
Review of the pharmacokinetics ...... essants: focus on venlafaxine.
@en
Review of the pharmacokinetics ...... essants: focus on venlafaxine.
@nl
type
label
Review of the pharmacokinetics ...... essants: focus on venlafaxine.
@ast
Review of the pharmacokinetics ...... essants: focus on venlafaxine.
@en
Review of the pharmacokinetics ...... essants: focus on venlafaxine.
@nl
prefLabel
Review of the pharmacokinetics ...... essants: focus on venlafaxine.
@ast
Review of the pharmacokinetics ...... essants: focus on venlafaxine.
@en
Review of the pharmacokinetics ...... essants: focus on venlafaxine.
@nl
P2860
P1476
Review of the pharmacokinetics ...... essants: focus on venlafaxine.
@en
P2093
P2860
P356
10.1002/1520-6394(2000)12:1+<30::AID-DA4>3.0.CO;2-G
P478
12 Suppl 1
P577
2000-01-01T00:00:00Z